Archive


Category: BAT1706 Proposed Biosimilar

  • Bio-Thera Reports MAA Submission to EMA for BAT1706 a Proposed Biosimilar to Avastin

    Shots: The company has submitted an MAAA for BAT1706 to EMA. Bio-Thera seeks a commercial license for all approved indications of bevacizumab in the EU Member States, Iceland, Norway, and Liechtenstein The submission of the MAA for BAT1706 marks it as the first ex-China MAA/ BLA submission. The BLA of the biosimilar for metastatic carcinoma […]